Is there evidence for continuing osimertinib (Tagrisso) while adding platinum‑pemetrexed chemotherapy in a 54‑year‑old woman with EGFR‑mutated non‑small cell lung cancer who progressed on adjuvant osimertinib and now presents with hepatic metastases?

Continuing Osimertinib with Chemotherapy After Progression

The standard approach after osimertinib progression without targetable resistance mechanisms is platinum-pemetrexed chemotherapy, but continuing osimertinib alongside chemotherapy remains empirical and is not currently supported by definitive evidence. 1

Current Evidence Status

The 2022 ESMO Expert Consensus explicitly states that "the option to continue osimertinib in combination with systemic chemotherapy at osimertinib progression remains empirical" 1. This is a critical distinction—while the combination is being explored, it lacks the robust evidence base needed for routine recommendation.

Key Guideline Positions

For patients progressing on osimertinib without targetable alterations:

• Standard treatment remains platinum-based chemotherapy with or without bevacizumab 1
• Osimertinib may be continued only in specific scenarios:
  • Slow disease progression without clinical deterioration (continue osimertinib alone until symptomatic progression) 1
  • Oligoprogression (continue osimertinib with local therapy like radiation/surgery) 1

The value of continuing osimertinib WITH chemotherapy is explicitly stated as "unknown" in multiple guideline statements 1

Why the Uncertainty?

The IMPRESS study demonstrated no improvement in PFS or OS with continuation of gefitinib plus chemotherapy at gefitinib progression 1. While osimertinib has a different pharmacologic profile (particularly CNS penetration), extrapolating benefit from gefitinib data to osimertinib is inappropriate, leaving this question unanswered 1.

Emerging Data (Not Yet Guideline-Supported)

Recent real-world and retrospective studies suggest potential benefit:

• Real-world data from Singapore/Hong Kong (2024): Pemetrexed-platinum plus osimertinib after first-line osimertinib failure showed median time to treatment failure of 6.6 months, with 81.7% achieving PR/SD 2

  • Critical finding: Starting chemotherapy within 20 days of osimertinib progression predicted superior outcomes (8.4 vs 6.0 months, p=0.03) 2
  • Intracranial disease control achieved in 90.6% of patients with measurable CNS metastases 2

• Multi-institutional retrospective (2021): Osimertinib plus chemotherapy in third-line or beyond showed median duration on treatment of 6.1 months with platinum doublet, with favorable CNS control (only 24% CNS progression among 84% with baseline CNS metastases) 3

• FLAURA2 trial context: While this trial showed benefit of upfront osimertinib plus chemotherapy (not at progression), it demonstrates the combination is feasible, though with increased toxicity (grade ≥3 AEs 64% vs 27%) 4, 5, 6

Practical Approach for Your Patient

For a 54-year-old woman with hepatic metastases after adjuvant osimertinib progression:

1. First priority: Obtain tissue/liquid biopsy to assess for:

   • MET amplification (10-15% of osimertinib resistance) 1
   • HER2 amplification
   • Histologic transformation (squamous or small-cell, up to 15%) 1
   • Other targetable alterations

2. If no targetable alterations found:

   • Standard recommendation: Platinum-pemetrexed chemotherapy (discontinue osimertinib) 1
   • Consider atezolizumab + bevacizumab + platinum-pemetrexed as alternative (based on IMpower-150 subgroup data showing HR 0.74 in TKI-pretreated patients) 1

3. If considering osimertinib continuation with chemotherapy (off-guideline):

   • This is empirical and should ideally be done in a clinical trial setting 1
   • Real-world data suggest potential benefit, particularly for CNS disease control 2, 3
   • If pursued, initiate chemotherapy within 20 days of documented progression based on real-world predictive data 2
   • Monitor closely for additive toxicity

Critical Caveats

• Hepatic metastases: No specific data addresses whether hepatic involvement influences the decision to continue osimertinib with chemotherapy
• Adjuvant vs. metastatic setting: Your patient progressed on adjuvant osimertinib, which may represent different biology than progression on first-line metastatic treatment
• Toxicity consideration: Grade ≥3 AEs are significantly higher with combination therapy (64-70% vs 27-34% with osimertinib alone) 4, 5, 7, 6
• No OS benefit demonstrated: Even in FLAURA2 (upfront combination), OS benefit was modest (HR 0.77) with significantly increased toxicity 6

Alternative Emerging Options (2024 ASCO Guidelines)

Amivantamab plus chemotherapy is now a guideline-supported option after osimertinib progression (MARIPOSA-2 trial: median PFS 6.3 vs 4.2 months with chemotherapy alone, HR 0.48) 4, 7, though this adds a bispecific antibody rather than continuing osimertinib.

Bottom line: Discontinue osimertinib and start platinum-pemetrexed chemotherapy as the evidence-based standard approach. Continuing osimertinib with chemotherapy lacks definitive supporting evidence and should only be considered in the context of a clinical trial or after exhausting standard options, with careful discussion of the empirical nature of this approach and increased toxicity risk.